Fatty liver and FGF21 physiology.

Area of Science:

• Hepatology
• Metabolic Regulation
• Endocrinology

Background:

• Non-alcoholic fatty liver disease (NAFLD) is a major cause of chronic liver dysfunction, strongly associated with rising obesity and metabolic syndrome rates.
• The precise molecular mechanisms underlying NAFLD pathogenesis are not fully understood, and effective therapeutic options beyond diet remain limited.
• Fibroblast growth factor 21 (FGF21) is a key metabolic regulator produced in the liver, influencing systemic metabolism and potentially liver health.

Purpose of the Study:

• To explore the physiological role of FGF21 in the context of liver disease.
• To investigate the potential of FGF21 as a therapeutic target for NAFLD.
• To understand how FGF21 impacts fat accumulation, inflammation, and fibrosis in the liver.

Main Methods:

• Review of existing scientific literature on FGF21 and NAFLD.
• Analysis of preclinical and clinical data regarding FGF21's effects on liver fat.
• Examination of studies investigating FGF21's impact on hepatic inflammation and fibrosis.

Main Results:

• Evidence suggests FGF21 administration can decrease hepatic fat accumulation.
• FGF21 treatment has been associated with reduced liver inflammation and fibrosis in various models.
• FGF21's complex systemic effects highlight its role as a metabolic regulator.

Conclusions:

• Understanding FGF21 physiology is crucial for advancing the comprehension of liver disease.
• FGF21 presents a promising therapeutic avenue for managing NAFLD and its associated complications.
• Targeting FGF21 pathways may offer novel strategies for treating fatty liver disease.